Inovio Biomedical Corp (NASDAQ:INO)

CAPS Rating: 2 out of 5

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.

Recs

5
Player Avatar zzlangerhans (99.82) Submitted: 5/16/2011 11:52:45 AM : Outperform Start Price: $3.53 INO Score: -52.48

For about a year and a half I've been biting away at Inovio with short-term underperforms and doing OK. I'm changing things up a little bit in order to take score leadership away from some red-thumber with a bomb charm.

It's a struggle to find positive things to say about Inovio. They're an uninspiring vaccine developer that hasn't run a phase III trial since the failure of the SECTA electrochemical tumor ablation process in 2007. But the share price is at its lowest point since the summer 2010 market swoon and seems to have stabilized. They have early stage clinical trials of DNA vaccines for HIV, hepatitis C, and avian flu in process as well as a phase II trial of cervical cancer vaccine VGX-3100. I'm not sure their track record justifies a market cap of 100M but given the historical performance of the stock I'll make it a CAPS-only positive for now.

Member Avatar NoFlash (< 20) Submitted: 7/10/2013 10:54:25 AM
Recs: 0

I have been following for the past 6 months plus. Good press from some analyst. Seems like their research is going better, and their has been insider buying. CEO owns 10%. Progress in both Avian flu vaccine and HIV. I have taken a small dollar position which has more than doubled in the past few weeks. Are you still following?

Featured Broker Partners


Advertisement